RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

O'Sullivan JM., Taylor J., Gerds A., Buckley S., Harrison CN., Oh S., List AF., Howard K., Dreau H., Hamblin A., Mead AJ.

DOI

10.1038/s41375-023-02027-3

Type

Journal article

Journal

Leukemia

Publication Date

10/2023

Addresses

NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. jennifer.osullivan@rdm.ox.ac.uk.

Permalink Original publication